Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?
<div><p>PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2019
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513515128094720 |
|---|---|
| author | Ghaneya Al-Khadairi (14153274) |
| author2 | Julie Decock (44558) |
| author2_role | author |
| author_facet | Ghaneya Al-Khadairi (14153274) Julie Decock (44558) |
| author_role | author |
| dc.creator.none.fl_str_mv | Ghaneya Al-Khadairi (14153274) Julie Decock (44558) |
| dc.date.none.fl_str_mv | 2019-07-15T06:00:00Z |
| dc.identifier.none.fl_str_mv | 10.3390/cancers11070984 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Cancer_Testis_Antigens_and_Immunotherapy_Where_Do_We_Stand_in_the_Targeting_of_PRAME_/25886938 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Oncology and carcinogenesis PRAME cancer testis antigen cancer vaccine adoptive T cell therapy immunotherapy antibody |
| dc.title.none.fl_str_mv | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <div><p>PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Cancers<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cancers11070984" target="_blank">https://dx.doi.org/10.3390/cancers11070984</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_58c294e57b8e2a5dd0c2deeb90faf3c0 |
| identifier_str_mv | 10.3390/cancers11070984 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/25886938 |
| publishDate | 2019 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME?Ghaneya Al-Khadairi (14153274)Julie Decock (44558)Biomedical and clinical sciencesImmunologyOncology and carcinogenesisPRAMEcancer testis antigencancer vaccineadoptive T cell therapyimmunotherapyantibody<div><p>PRAME or PReferentially expressed Antigen in Melanoma is a testis-selective cancer testis antigen (CTA) with restricted expression in somatic tissues and re-expression in various cancers. It is one of the most widely studied CTAs and has been associated with the outcome and risk of metastasis. Although little is known about its pathophysiological function, PRAME has gained interest as a candidate target for immunotherapy. This review provides an update on our knowledge on PRAME expression and function in healthy and malignant cells and the current immunotherapeutic strategies targeting PRAME with their specific challenges and opportunities. We also highlight some of the features that position PRAME as a unique cancer testis antigen to target.</p><p> </p></div><h2>Other Information</h2> <p> Published in: Cancers<br> License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/cancers11070984" target="_blank">https://dx.doi.org/10.3390/cancers11070984</a></p>2019-07-15T06:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.3390/cancers11070984https://figshare.com/articles/journal_contribution/Cancer_Testis_Antigens_and_Immunotherapy_Where_Do_We_Stand_in_the_Targeting_of_PRAME_/25886938CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/258869382019-07-15T06:00:00Z |
| spellingShingle | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? Ghaneya Al-Khadairi (14153274) Biomedical and clinical sciences Immunology Oncology and carcinogenesis PRAME cancer testis antigen cancer vaccine adoptive T cell therapy immunotherapy antibody |
| status_str | publishedVersion |
| title | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| title_full | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| title_fullStr | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| title_full_unstemmed | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| title_short | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| title_sort | Cancer Testis Antigens and Immunotherapy: Where Do We Stand in the Targeting of PRAME? |
| topic | Biomedical and clinical sciences Immunology Oncology and carcinogenesis PRAME cancer testis antigen cancer vaccine adoptive T cell therapy immunotherapy antibody |